Regeneron Reports Third Quarter 2017 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Regeneron Pharma (REGN) PT Raised to $440 at SunTrust Robinson Humphrey
November 9, 2017 3:47 PM ESTSunTrust Robinson Humphrey analyst Suneja Yatin raised the price target on Regeneron Pharma (NASDAQ: REGN) to $440.00 (from $435.00) while maintaining a Hold rating following Q3 results highlighted by Eylea U.S. sales (+3.7% Q/Q), above (+2.1%) consensus.
The firm views near-term catalysts (Dupi in Asthma, anti-PD-1 in CSCC) as already priced-in.
... MoreRegeneron Pharma (REGN) PT Lowered to $465 at Jefferies
November 9, 2017 8:15 AM ESTJefferies lowered its price target on Regeneron Pharma (NASDAQ: REGN) to $465.00 (from $500.00) while maintaining a Hold rating.
... More